Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla's stock experienced a decline in today's session, with the price decreasing by 1.45% to Rs 1498.10. There was high ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

Cipla Ltd reported a robust 30% YoY increase in consolidated net profit, reaching Rs 1,222 crore for Q4 FY25, driven by ...

Shares of pharmaceutical giant Cipla dropped almost two per cent in early trading despite positive brokerage reports ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

Cipla celebrates a significant 30% rise in net profit for Q4 FY25, with revenues growing by 9%. The company emphasizes its ...

Cipla beats profit estimates with strong demand for chronic condition drugs, faces supply chain issues for tumour drug.